Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report 2026

Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Overview

• Ribonucleic Acid (RNA)-Based Oncolytic Therapy market size has reached to $2.12 billion in 2025 • Expected to grow to $4.94 billion in 2030 at a compound annual growth rate (CAGR) of 18.4% • Growth Driver: Growing Adoption Of Personalized Medicine Fueling The Growth Of The Market Due To Increasing Demand For Targeted And Patient-specific Treatments • Market Trend: Innovations In mRNA-Lipid Nanoparticle Delivery Systems Boosting Market Growth • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?

Ribonucleic acid (RNA)-based oncolytic therapy is a cancer treatment that uses engineered RNA viruses to selectively infect and kill tumor cells. These viruses replicate in cancer cells, causing their destruction and releasing tumor antigens. This also stimulates the immune system to recognize and attack remaining cancer cells, enhancing overall anti-tumor efficacy. The main therapy types of ribonucleic acid (RNA)-based oncolytic therapy are messenger ribonucleic acid (mRNA)-based oncolytic therapy, small interfering ribonucleic acid (siRNA)-based oncolytic therapy, micro ribonucleic acid (miRNA)-based oncolytic therapy, and other therapy types. Messenger ribonucleic acid (mRNA)-based oncolytic therapy refers to the use of synthetic mRNA molecules engineered to stimulate the immune system or directly induce tumor cell death, offering a targeted and adaptable approach to cancer treatment. These therapies are administered through routes such as intravenous, intratumoral, and other methods, and are applied in breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, and others. The key end-users include hospitals, cancer research institutes, specialty clinics, and others.

What Is The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Growth Forecast?

The ribonucleic acid (rna)-based oncolytic therapy market size is expected to see rapid growth in the next few years. It will grow to $4.94 billion in 2030 at a compound annual growth rate (CAGR) of 18.4%. The growth in the forecast period can be attributed to increasing approvals of rna-based cancer therapies, rising demand for personalized oncology treatments, expansion of immuno-oncology pipelines, growing investment in gene and cell therapies, technological advancements in rna delivery systems. Major trends in the forecast period include increasing advancement of rna virus engineering, rising adoption of combination oncolytic therapies, growing focus on immune system activation, expansion of targeted tumor-specific rna therapies, enhanced integration of precision oncology tools.

Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Segmentation

1) By Therapy Type: Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy, Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy, Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy, Other Therapy Types 2) By Route Of Administration: Intravenous, Intratumoral, Other Route Of Administrations 3) By Application: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Other Applications 4) By End-User: Hospitals, Cancer Research Institutes, Specialty Clinics, Other End-Users Subsegments: 1) By Messenger Ribonucleic Acid (mRNA)-Based Oncolytic Therapy: Self-Amplifying mRNA (saRNA), Non-Replicating mRNA, Circular RNA (circRNA)-Based mRNA therapy 2) By Small Interfering Ribonucleic Acid (siRNA)-Based Oncolytic Therapy: Chemically Modified siRNA, Nanoparticle-Delivered siRNA, Conjugated siRNA 3) By Micro Ribonucleic Acid (miRNA)-Based Oncolytic Therapy: miRNA Mimics, miRNA Inhibitors (Antagomirs), miRNA Aponges Or Decoys 4) By Other Therapy Types: Long Non-Coding RNA (lncRNA)-Based Therapies, Short Hairpin RNA (shRNA)-Based Therapies, Aptamer-RNA Based Oncolytic Agents

What Is The Driver Of The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?

The growing adoption of personalized medicine is expected to propel the growth of the RNA-based oncolytic therapy market going forward. Personalized medicine refers to medical treatments tailored to individual genetic profiles, improving efficacy and reducing adverse effects. The adoption of personalized medicine is increasing as more healthcare providers and institutions recognize the potential to enhance patient outcomes through targeted therapies and precision diagnostics. RNA-based oncolytic therapy plays a crucial role in cancer care by aligning with the growing adoption of personalized medicine to deliver targeted and patient-specific treatment approaches. For instance, in February 2024, the Personalized Medicine Coalition, a US-based advocacy group for tailored medical treatments, the FDA approved 16 new personalized treatments for rare disease patients in 2023, up from 6 in 2022. Therefore, the growing adoption of personalized medicine is driving the RNA-based oncolytic therapy market.

Key Players In The Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market

Major companies operating in the ribonucleic acid (rna)-based oncolytic therapy market are AstraZeneca PLC, Moderna Inc., BioNTech SE, Gritstone Bio Inc., Orna Therapeutics Inc., Strand Therapeutics Inc., Oncolytics Biotech Inc., Anima Biotech Inc., eTheRNA immunotherapies NV, Vyriad Inc., Haya Therapeutics Inc., Virogin Biotech Inc., Providence Therapeutics Holdings Inc., Sirnaomics Inc., Humane Genomics Inc., Replicate Bioscience Inc., Abogen Biosciences Inc., Chimeron Bio Inc., Aro Biotherapeutics Inc., TransCode Therapeutics Inc.

Global Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Trends and Insights

Major companies are operating in the ribonucleic acid (RNA)-based oncolytic therapy market, focusing on developing technological advancements such as synthetic messenger RNA (mRNA) technology to enhance tumor-targeting efficiency, improve immune activation, and achieve more precise and durable cancer treatment outcomes. Synthetic messenger RNA (mRNA) technology is a biotechnology approach that designs and delivers lab-made mRNA sequences to direct cells to produce specific therapeutic proteins for disease treatment, including cancer. For instance, in June 2024, CSPC Pharmaceutical Group Limited, a China-based pharmaceutical company, received regulatory approval in China to initiate clinical trials for SYS6020, its synthetic mRNA-based cancer cell therapy. This development represents a major advancement in the country’s messenger RNA therapeutics landscape. SYS6020 employs mRNA-lipid nanoparticle technology to selectively target and eliminate myeloma cancer cells with minimal adverse effects, while also demonstrating potential applications in the treatment of certain autoimmune diseases.

What Are Latest Mergers And Acquisitions In The Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?

In June 2023, Charles River Laboratories International, Inc., a US-based contract research organization (CRO), partnered with Curigin Co., Ltd. to produce oncolytic RNAi gene therapy. With this collaboration, the aim is to advance the development and manufacturing of Curigin’s RNAi-based oncolytic gene therapies by leveraging Charles River’s CDMO expertise to support preclinical and clinical trials. Curigin Co. Ltd. is a South Korea-based biotechnology company specializing in the development of RNA interference (RNAi)-based oncolytic gene therapies for cancer treatment.

Regional Insights

North America was the largest region in the ribonucleic acid (RNA)-based oncolytic therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market?

The ribonucleic acid (RNA)-based oncolytic therapy market includes revenues earned by entities through services such as clinical trials, tumor targeting, immune monitoring, patient support, and treatment administration. The market value includes the value of related goods sold by the service provider or included within the service offering. The ribonucleic acid (RNA)-based oncolytic therapy market also includes sales of RNA oncolytic viruses, viral vectors, delivery systems, formulations, and diagnostic kits. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ribonucleic Acid (RNA)-Based Oncolytic Therapy Market Report 2026?

The ribonucleic acid (rna)-based oncolytic therapy market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ribonucleic acid (rna)-based oncolytic therapy industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.